Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients
Transplant International · 31.01.2024 · 37
DOI: 10.3389/ti.2024.12320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 31.01.2024. Verfasst von Tasneem R Abdel-Karim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Diabetes Mellitus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institutes of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The instant blood-mediated inflammatory response (IBMIR) causes islet loss and compromises diabetes outcomes after total pancreatectomy with islet autotransplant (TPIAT). We previously reported a possible benefit of etanercept in maintaining insulin secretion 3 months post-TPIAT. Here, we report 2-year diabetes outcomes and peri-operative inflammatory profiles from a randomized trial of etanercept and alpha-1 antitrypsin (A1AT) in TPIAT. We randomized 43 TPIAT recipients to A1AT (90 mg/kg IV x6 doses, n = 13), etanercept (50 mg then 25 mg SQ x 5 doses, n = 14), or standard care ( n = 16). Inflammatory cytokines, serum A1AT and unmethylated insulin DNA were drawn multiple times in the perioperative period. Islet function was assessed 2 years after TPIAT with mixed meal tolerance test, intravenous glucose tolerance test and glucose-potentiated arginine induced insulin secretion. Cytokines, especially IL-6, IL-8, IL-10, and MCP-1, were elevated during and after TPIAT. However, only TNFα differed significantly between groups, with highest levels in the etanercept group ( p = 0.027). A1AT increased after IAT in all groups ( p < 0.001), suggesting endogenous upregulation. Unmethylated insulin DNA ratios (a marker of islet loss) and 2 years islet function testing were similar in the three groups. To conclude, we found no sustained benefit from administering etanercept or A1AT in the perioperative period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.
- Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, United States.
- Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT, United States.
- Department of Surgery, University of Minnesota, Minneapolis, MN, United States.
- Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, United States.
- Department of Surgery, Stanford University, Palo Alto, CA, United States.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Abdel-Karim, T. R., Hodges, J. S., Herold, K. C., Pruett, T. L., Ramanathan, K. V., Hering, B. J., Dunn, T. B., Kirchner, V. A., Beilman, G. J., & Bellin, M. D. (2024). Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International, 37. https://doi.org/10.3389/ti.2024.12320
Vancouver
Abdel-Karim TR, Hodges JS, Herold KC, Pruett TL, Ramanathan KV, Hering BJ, et al. Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International. 2024;37. doi:10.3389/ti.2024.12320
BibTeX
@article{AbdelKarim2024,
author = {Abdel-Karim, Tasneem R and Hodges, James S and Herold, Kevan C and Pruett, Timothy L and Ramanathan, Karthik V and Hering, Bernhard J and Dunn, Ty B and Kirchner, Varvara A and Beilman, Gregory J and Bellin, Melena D},
title = {Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients},
journal = {Transplant International},
year = {2024},
volume = {37},
doi = {10.3389/ti.2024.12320}
}
EUVIMED